Decision Diagnostics EBIT

The latest EBIT for DECN is $-2.1M as of September 2021. That compares with $-1.4M in the prior-year period — down 46.5% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside Decision Diagnostics's historical trend and sector peers before judging valuation or financial health.

Over the past year, DECN's EBIT moved from $-1.4M to $-2.1M — a 46.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Decision Diagnostics's operating scale or balance-sheet position.

Against its sector companies, DECN currently prints $-2.1M for EBIT, while the sector average sits near $2.5T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Decision Diagnostics's growth, margins, and balance sheet.

A EBIT figure of $-2.1M for DECN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting DECN's EBIT ($-2.1M), review year-over-year change from $-1.4M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.